Article

Transplantations-assoziierte Lymphoproliferationen

Der Pathologe (Impact Factor: 0.64). 03/2011; 32(2):152-158. DOI: 10.1007/s00292-010-1407-x

ABSTRACT Die Transplantation von soliden Organen und Knochenmark erfordert zur Verhinderung einer Abstoßungsreaktion eine medikamentöse
Immunsuppression, die dosis- und medikamentenabhängig die Entstehung von Epstein-Barr-Virus- (EBV-)assoziierten Posttransplantationslymphoproliferationen
(„post-transplant lymphoproliferative disease“, PTLD) begünstigt. Dabei gibt es ein Spektrum von Läsionen, die von der Hyperplasie
bis zum manifesten Lymphom reichen. Letzteres wird als monomorphe PTLD bezeichnet. Hyperplastische Veränderungen, die von
viralen Reaktionen nicht zu unterscheiden sind, werden als frühe oder Mononukleose-ähnliche Läsionen bezeichnet, solche, bei
denen die Lymphknotenarchitektur aufgehoben ist oder extranodale Herde entstehen, ohne dass ein lymphomartiger Phänotyp nachweisbar
ist, als polymorphe PTLD. Bei den monomorphen PTLD handelt es sich entweder um hochmaligne B-Zell-Lymphome, Plasmazellneoplasien
oder Hodgkin-Lymphome und nur sehr selten um T-Zell-Lymphome. Niedrig maligne B-Zell-Lymphome treten nicht auf. Eine Reduktion
der Immunsuppression kann bei einem Teil der Fälle einschließlich der monomorphen PTLD den Prozess zum Stillstand bringen.

Transplantation of solid organs and haematopoietic stem cells requires immunosuppressive drug therapy in order to prevent
rejection or graft-versus-host disease. Depending on dosage and type of drug, the risk of developing an Epstein-Barr virus
(EBV)-associated post-transplant lymphoproliferative disease (PTLD) is increased. The lesion spectrum ranges from hyperplastic
lesions to manifest lymphomas, the latter being classified as monomorphic PTLD. Hyperplastic changes, which are not distinguishable
from viral reactions, comprise early or mononucleosis-like lesions. Those with effaced lymph node architecture or extranodal
manifestation without a lymphoma-like phenotype are designated polymorphic PTLD. Monomorphic PTLD are either high grade B
cell lymphomas, plasma cell neoplasms or Hodgkin lymphomas and only very rarely T cell lymphomas. Low grade B cell lymphomas
do not occur. In a subfraction of cases, including even monomorphic PTLD, reduction of immunosuppression alone is sufficient
to induce remission of the pathological process.

SchlüsselwörterOrgantransplantation–Posttransplantationslymphoproliferation–Epstein-Barr-Virus–Lymphome–Immunsuppression
KeywordsOrgan transplantation–Post-transplant lymphoproliferative disease–Epstein-Barr virus–Lymphoma–Immunosuppression

0 Followers
 · 
95 Views
 · 
0 Downloads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transplantation of solid organs and hematopoietic stem cells is accompanied by profound disturbance of immune function mediated by immunosuppressive drugs or delayed immune reconstitution. Disturbed T cell control of Epstein-Barr virus (EBV)-infected B cells leads to posttransplant lymphoproliferative disorder (PTLD) in up to 10% of patients. Children are at a higher risk because they are more often EBV-naïve before transplantation. Patients with PTLD often present with unspecific symptoms (pain and organ/graft dysfunction). Depending on the onset of PTLD, manifestations vary between mainly nodal (late PTLD) and extranodal sites (early PTLD). Histology, immunohistology, EBER in situ hybridization and molecular pathology are required for diagnosis and subclassification of PTLD. The three major types are early lesions (resembling reactive proliferations in immunocompetent patients), polymorphic PTLD (proliferation of B and T cells with effacement of histoarchitecture) and monomorphic PTLD (presenting as malignant lymphomas, mainly high-grade B cell lymphomas). In a subfraction of cases, including monomorphic PTLD, reduction of immunosuppressive medication alone is sufficient to induce remission. Surgical debulking of tumor mass and anti-CD20-antibody treatment with or without chemotherapy (usually at lower dosages than in immunocompetent patients) constitute the basis of additional therapy.
    Pathobiology 01/2013; 80(6):289-96. DOI:10.1159/000350331 · 2.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients after solid organ transplantation (SOT) carry a substantially increased risk to develop malignant lymphomas. This is in part due to the immunosuppression required to maintain the function of the organ graft. Depending on the transplanted organ, up to 15% of pediatric transplant recipients acquire posttransplant lymphoproliferative disease (PTLD), and eventually 20% of those succumb to the disease. Early diagnosis of PTLD is often hampered by the unspecific symptoms and the difficult differential diagnosis, which includes atypical infections as well as graft rejection. Treatment of PTLD is limited by the high vulnerability towards antineoplastic chemotherapy in transplanted children. However, new treatment strategies and especially the introduction of the monoclonal anti-CD20 antibody rituximab have dramatically improved outcomes of PTLD. This review discusses risk factors for the development of PTLD in children, summarizes current approaches to therapy, and gives an outlook on developing new treatment modalities like targeted therapy with virus-specific T cells. Finally, monitoring strategies are evaluated.
    Clinical and Developmental Immunology 09/2013; 2013(10):814973. DOI:10.1155/2013/814973 · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abdominal complications after thoracic transplantation (Tx) are potentially associated with an increased risk of mortality. We recently reported about the severe outcome after bowel perforation in patients following lung transplantation (LuTx). The aim of the present study was to likewise identify the risk factors with an impact on patient survival following heart transplantation (HTx). A retrospective analysis for the frequency and outcome of abdominal interventions following HTx was performed in 342 patients, and these data thereafter compared to a re-evaluated pool of 1,074 patients following LuTx. All patients were transplanted at Hanover Medical School, Germany, between January 2000 and October 2011. The incidence for abdominal surgery was comparable between patients following HTx (n = 33; 9.6 %) and LuTx (n = 90; 8.4 %). Elective operations were more frequently performed in patients after HTx (8.5 vs. 5.1 %). In contrast, the incidence of emergency interventions was higher after LuTx (5.3 %) than that following HTx (2.3 %). Herewith associated was the mortality observed in these transplant recipients (15.3 and 9.9 % for LuTx and HTx, respectively). Leading diagnosis for emergency surgery was bowel perforation (n = 18, regarding all cases). In 11 of these patients, perforation occurred within the first 6 months after Tx and eight of them died in the course of this complication (one patient after HTx and seven patients after LuTx). Abdominal complications after HTx are less frequently than after LuTx but equally correlate with a high mortality rate. In finding or even reasonable suspicion of an acute abdomen after thoracic Tx, a broad practice for extended diagnostics and a low barrier for an early explorative laparotomy thus are recommended.
    Langenbeck s Archives of Surgery 04/2014; 399(6). DOI:10.1007/s00423-014-1193-7 · 2.16 Impact Factor
Show more